Daniel Haverstock - Concepedia

Author

Daniel Haverstock

Also Known As

D HAVERSTOCK, D Haverstock, D. Haverstock, D.C. Haverstock, DANIEL C. HAVERSTOCK, DANIEL HAVERSTOCK, Daniel C Haverstock, Daniel C. Haverstock, Daniel Haverstock, Daniel C. Haverstock

Publications

Citations

H-Index

Concepts

All Affiliations

Bayer (United States)The University of Texas Health Science Center at San Antonio Bayer (Canada)State University of New York Stony Brook University

About

Daniel Haverstock is an author at Bayer (United States) specializing in medicine, antibiotics, and infection control.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	927
2	Health Sciences	2	2	100
3	Geriatrics	2	2	60
4	Engineering	1	1	25
5	Public Health	1	1	25

Daniel Haverstock

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Results of a Randomized Trial Comparing Sequential Intravenous/Oral Treatment with Ciprofloxacin Plus Metronidazole to Imipenem/Cilastatin for Intra-Abdominal Infections Joseph S. Solomkin, Harald H. Reinhart, E. Patchen Dellinger, Annals of Surgery	1996	191
Definition of the role of enterococcus in intraabdominal infection: Analysis of a prospective randomized trial Robert Burnett, Daniel Haverstock, E. Patchen Dellinger, Surgery Antimicrobial SusceptibilityMicrobial DiseaseClinical InfectionIntraabdominal InfectionMicrobiology	1995	173
Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis Sanford Chodosh, C. Andrew DeAbate, Daniel Haverstock, Respiratory Medicine Acute Bacterial ExacerbationsLung InflammationChronic BronchitisRespiratory InfectionInfectious Respiratory Disease	2000	136
Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis Marc Miravitlles, Frank Kruesmann, Daniel Haverstock, European Respiratory Journal Sputum ColourAntibioticsRespiratory DiseasesChronic Bronchitis ExacerbationsAecb Patients	2011	98
Comparison of Intravenous/Oral Ciprofloxacin Plus Metronidazole Versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections Stephen M. Cohn, Pamela A. Lipsett, Timothy G. Buchman, Annals of Surgery	2000	95
Cystic fibrosis clinical score: A new scoring system to evaluate acute pulmonary exacerbation Jamshed F. Kanga, Robert J. Kuhn, Lois Craigmyle, Clinical Therapeutics Acute Lung InjuryPulmonary CareInflammatory Lung DiseaseAdvanced Lung DiseaseNew Scoring System	1999	80
Moxifloxacin<i>versus</i>amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results Robert Wilson, Antonio Anzueto, Marc Miravitlles, European Respiratory Journal	2011	74
Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations Deborah Church, JAMSHED F. KANGA, Robert J. Kuhn, The Pediatric Infectious Disease Journal	1997	73
Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women Dan Henry, Robert Bettis, Ernie Riffer, Clinical Therapeutics UrologyAntimicrobial StewardshipAntibioticsConventional Twice-daily CiprofloxacinFemale Urology	2002	65
Ciprofloxacin plus Piperacillin Compared with Tobramycin plus Piperacillin as Empirical Therapy in Febrile Neutropenic Patients James E. Peacock, D A Herrington, James C. Wade, Annals of Internal Medicine	2002	59

Page 1